ชื่อผู้ได้มา/จำหน่าย :?OVERSEAS GROWTH FUND INC. | ประเภทหลักทรัพย์ : หุ้น | วันที่มีหน้าที่ : 10/05/2549
ชื่อผู้ได้มา/จำหน่าย :?TRIPLE GROWTH INTERNATIONAL LIMITED | ประเภทหลักทรัพย์ : หุ้น | วันที่มีหน้าที่ : 30/09/2554
% yoy. EBITDA margin rose from 26% of hospital revenue in 3Q18 to 28% in 3Q19. The promising EBITDA was attributable to not only the revenue growth but also the effective cost control as mentioned above
subsidiary (AMARC) showing 18.65% of revenues’ growth compared with last year; whilst with qualified performance to efficiently manage overall costs and expenses to be up only 10.38% from last year even
has risen by 25.6%, but net earned premium has only gained 12.1%. This is because long-term insurance policies contributed to a certain portion of sales growth. Earning those premiums in a given period
”), the subsidiary, has indicated the growth by 12.35%. Costs and Expenses The Company reported the consolidated costs and expenses for Q3/2019 of Baht 365.61 million representing a slightly increase by
Economic Community (AEC), Thai capital market must be prompt for rapid change coming with wider business opportunity, economic growth and fierce competition. The SEC will keep close eyes on the development
unlocking government budget expenditures and witnessing a rebound in exports and tourism approaching pre-pandemic levels. Projections suggest a robust growth trajectory for Thailand's economy this year and
favorable growth at 11.3%, mainly from the continued success of Babi Mild and stronger Twelve Plus brands. International business grew at 10.4% at constant FX rate, while the reported figures grew only at 0.6